Toward an HIV vaccine: A scientific journey

See allHide authors and affiliations

Science  24 Jul 2015:
Vol. 349, Issue 6246, pp. 386-387
DOI: 10.1126/science.aac6300

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


In the face of a global pandemic, the search for an effective vaccine against the human immunodeficiency virus (HIV) remains an urgent priority. From the first HIV vaccine trials in the 1980s to the present, a tension has existed between the desire to move quickly to clinical trials to stem the spread of the epidemic and the view that research into HIV pathogenesis and host immunity were necessary predicates to and informative of vaccine design. Those advocating the first strategy—an empirical (or inductive) approach—argued that in vitro and animal studies were poorly predictive of the human response to HIV infection and that the only way to gauge vaccine efficacy was to test candidates in humans. Those advocating the second strategy—a theoretical (or deductive) approach—hoped to establish an understanding of the immune response to natural infection and to find ways to recapitulate and enhance that response through vaccination. Today, these approaches are coalescing into concomitant paths toward a safe and effective HIV vaccine.